Aktis Oncology, Inc. (NASDAQ:AKTS)
| Market Cap | 913.22M-22.6% |
| Revenue (ttm) | 10.06M |
| Net Income | -73.14M |
| EPS | -1.05 |
| Shares Out | 53.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,670.25 |
| Open | 17.86 |
| Previous Close | 18.00 |
| Day's Range | 16.99 - 17.86 |
| 52-Week Range | 14.72 - 34.19 |
| Beta | 0.45 |
| Analysts | Buy |
| Price Target | 37.40(+118.71%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About AKTS
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$AKTS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AKTS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AKTS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AKTS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AKTS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AKTS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AKTS
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $15.16M |
| IWMiShares Russell 2000 ETF | $13.35M |
| XBIState Street SPDR S&P Biotech ETF | $9.54M |
| VXFVanguard Extended Market ETF | $5.61M |
| IWOiShares Russell 2000 Growth ETF | $3.30M |
| VTWOVanguard Russell 2000 ETF | $3.16M |
Estimated from each fund’s disclosed top holdings × AUM
AKTS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AKTS’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score